AA
KRYS icon

AlphaCentric Advisors’s Krystal Biotech KRYS Stock Holding History

AlphaCentric Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$495K Buy
1,918
+105
+6% +$27.9K 0.49% 62
2025
Q4 		$447K Buy
+1,813
New +$382K 0.45% 68
2024
Q4 		$231K Buy
+1,474
New +$261K 0.23% 107

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AlphaCentric Advisors's KRYS Position: Q1 2026 in Review

AlphaCentric Advisors increased its Krystal Biotech (KRYS) stake by 5.8% in Q1 2026, buying an estimated $27.9K and bringing the position to 1,918 shares worth $495K. The position accounts for 0.49% of the portfolio, ranked #62.

AlphaCentric Advisors first reported a position in KRYS in Q4 2024 and has held it in 3 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • AlphaCentric Advisors held 1,918 shares of Krystal Biotech worth $495K as of Q1 2026.
  • AlphaCentric Advisors bought 105 Krystal Biotech shares in Q1 2026, an estimated $27.9K.
  • Krystal Biotech made up 0.49% of AlphaCentric Advisors's portfolio in Q1 2026, its #62 holding.
  • AlphaCentric Advisors first reported a position in Krystal Biotech in Q4 2024 and has held it in 3 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on AlphaCentric Advisors's 13F filing for Q1 2026, filed 7 May 2026.